UNIVERSITY PARK, Pa. -- L-type calcium channel blockers (LCCBs) -- the most widely used drugs for treating hypertension -- may harm the heart as much as help it, according to a new study. The research ...

NEW YORK, July 31 (Praxis Press) Cardiovascular outcomes have not been compared in hypertensive patients treated with calcium channel blockers and in patients treated with older drugs. Hansson and ...

February 6, 2008 — Results of a large case-control study suggest that current use of calcium-channel blockers, but not other antihypertensive agents, is associated with a significantly reduced risk ...

Please provide your email address to receive an email when new articles are posted on . Beta-blockers more effectively reduce risk for death or hospitalization in people with HFpEF compared with ...

Active ingredient: Clevidipine butyrate emulsion 0.5 mg/mL; solution for IV infusion; contains lipids 0.2 g/mL (soybean oil, egg phospholipids). Indication: To reduce BP when oral therapy is not ...

A new retrospective analysis of data from over 400,000 UK Biobank participants has revealed that calcium channel blockers (CCBs), but not other antihypertensive agents, were associated with an ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...